Mark Bach
Chief Medical Officer GentiBio
Seminars
Thursday 4th December 2025
Panel Discussion: Evaluating the Future of Autologous & Allogeneic Therapies
11:30 am
- Evaluating the autologous and allogeneic cell therapy space
- Identify the optimal approach to maximize therapeutic efficacy
- Consider patient safety by addressing challenges related to rejection and adverse immune responses in both autologous and allogeneic therapies
- Evaluate if autologous or allogeneic therapies are best for future autoimmune therapy personalization
Thursday 4th December 2025
Harnessing Insights from GentiBio’s Hypo-Immune Allogeneic Cell Therapy Platform to Advance Allogeneic Cell Therapies
1:45 pm
- Explore GNTI-122 autologous Type 1 Diabetes therapy
- Discuss GentiBio’s GNTI-350 hypo-immune allogeneic therapy to uncover key data guiding next-generation autoimmune treatment
- Evaluate the unique characteristics of hypo-immune allogeneic cell therapies over traditional allogeneic approaches
- Apply translational insights to accelerate the progression of allogeneic therapies for autoimmune indications
